What is claimed is:

1. A method for localized chemodenervation comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of an antibiotic and a pharmaceutically acceptable carrier.

2. A method for localized chemodenervation comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of an aminoglycoside antibiotic or an analog or derivative thereof and a pharmaceutically acceptable carrier.

3. The method of claim 2, wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

4. The method of claim 2, wherein the pharmaceutical composition further comprises a magnesium salt or an organic magnesium compound.

5. A method for localized chemodenervation comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of a polymyxin or an analog or derivative thereof and a pharmaceutically acceptable carrier.

6. The method of claim 5, wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

7. The method of claim 5, wherein the pharmaceutical composition further comprises a magnesium salt or an organic magnesium compound.

8. A method for localized chemodenervation comprising topically administering a pharmaceutical composition for comprising a pharmaceutically effective amount of tetracycline or an analog or derivative thereof and a pharmaceutically acceptable carrier.

9. A method for localized chemodenervation comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of lincosamide or an analog or derivative thereof and a pharmaceutically acceptable carrier.

10. The method of claim 9 wherein the lincosamide is clindamycin or lincomycin.

11. A method for localized chemodenervation comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of a muscle relaxant or an analog or derivative thereof and pharmaceutically acceptable carrier.

12. The method of claim 11 wherein the muscle relaxant is a non-depolarizing agent.

13. The method of claim 12 wherein the non-depolarizing agent is pancuronium, vecuronium, mivacurium or rocuronium.

14. The method of claim 11 wherein the muscle relaxant is a depolarizing agent.

15. The method of claim 14 wherein the depolarizing agent is succinylcholine or decamethonium.

16. The method of claim 11 wherein the muscle relaxant is a magnesium salt or an organic magnesium compound.

17. A method for localized chemodenervation comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of a plant extract or analog or derivative thereof, and a pharmaceutically acceptable carrier.

18. The method of claim 17, wherein the plant extract is toosendanin, coryneine, banana truck extract, or curare or black cohosh.

19. The method of claim 17, wherein the pharmaceutical composition further comprises a magnesium salt or an organic magnesium compound.

20. A method for treating involuntary facial muscle spasms comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of composition selected from the group consisting of aminoglycoside antibiotic, polymyxin, tetracycline, lincosamide, muscle relaxant and plant extract, or an analog or derivative thereof and a pharmaceutically acceptable carrier.

21. The method of claim 20, wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

22. The method of claim 20, wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

23. The method of claim 20, wherein the plant extract is toosendanin, coryneine, banana truck extract, curare or black cohosh.

24. The method of claim 20, wherein the pharmaceutical composition further comprises a magnesium salt or an organic magnesium compound

25. The method of claim 20 wherein the involuntary facial muscle spasms are caused by synkinesis, ocular disorders, dystonia, hemifacial spasm, or blepharospasm.

26. A method for reducing facial wrinkles comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of composition selected from the group consisting of aminoglycoside antibiotic, polymyxin, tetracycline, lincosamide, muscle relaxant and plant extract, or an analog or derivative thereof and a pharmaceutically acceptable carrier.

27. The method of claim 26, wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

28. The method of claim 26, wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

29. The method of claim 26, wherein the plant extract is toosendanin, coryneine, banana truck extract, curare or black cohosh.

30. The method of claim 26, wherein the pharmaceutical composition further comprises a magnesium salt or an organic magnesium compound.

31. A method for treating or reducing neuropathic pain comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of composition selected from the group consisting of aminoglycoside antibiotic, polymyxin, tetracycline, lincosamide, muscle relaxant and plant extract, or an analog or derivative thereof and a pharmaceutically acceptable carrier.

32. The method of claim 31, wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

33. The method of claim 31, wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

34. The method of claim 31, wherein the plant extract is toosendanin, coryneine, banana truck extract, curare or black cohosh.

35. The method of claim 31, wherein the pharmaceutical composition further comprises a magnesium salt or an organic magnesium compound.

36. The method of claim 31 wherein the neuropathic pain is caused by postherpetic neuralgia, diabetic neuropathy, complex regional pain syndrome, spinal cord injury, radiculopathy, migraine headache, myofascial pain, or carpal tunnel syndrome.

37. A pharmaceutical composition for topical administration for localized chemodenervation comprising pharmaceutically effective amounts of
a polymyxin or an analog or derivative thereof and
a magnesium salt or organic magnesium compound
in a pharmaceutically acceptable medium compatible with human skin.

38. The method of claim 37 wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

39. The pharmaceutical composition of claim 38 wherein the amount of polymyxin B is between about 800 U/g and about 80,000 U/g.

40. The pharmaceutical composition of claim 38 wherein the amount of polymyxin B nonapeptide is between about 0.04 mg/ml and about 400 mg/ml.

41. The pharmaceutical composition of claim 37 wherein the magnesium salt is magnesium sulfate.

42. The pharmaceutical composition of claim 41 wherein the amount of magnesium sulfate is between about 2 mg/g and about 200 mg/g.

43. A pharmaceutical composition for topical administration for localized chemodenervation comprising pharmaceutically effective amounts of
an aminoglycoside antibiotic or an analog or derivative thereof and
a magnesium salt or organic magnesium compound
in a pharmaceutically acceptable medium compatible with human skin.

44. The pharmaceutical composition of claim 43 wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

45. The pharmaceutical composition of claim 44 wherein the amount of neomycin is between about 2.5 mg/g and about 200mg/g.

46. The pharmaceutical composition of claim 43 wherein the magnesium salt is magnesium sulfate.

47. The pharmaceutical composition of claim 46 wherein the amount of magnesium sulfate is between about 2 mg/g and about 200 mg/g.

48. A pharmaceutical composition for topical administration for localized chemodenervation comprising pharmaceutically effective amounts of
plant extract or an analog or derivative thereof and
a magnesium salt or organic magnesium compound
in a pharmaceutically acceptable medium compatible with human skin.

49. The pharmaceutical composition of claim 48 wherein the plant extract is toosendanin, coryneine, banana truck extract, curare or black cohosh.

50. The pharmaceutical composition of claim 49 wherein the amount of black cohosh is between about 0.01 ml/g and about 1 ml/g.

51. The pharmaceutical composition of claim 48 wherein the magnesium salt is magnesium sulfate.

52. The pharmaceutical composition of claim 51 wherein the amount of magnesium sulfate is between about 2 mg/g and about 200 mg/g.

53. A pharmaceutical composition for topical administration for localized chemodenervation comprising a pharmaceutically effective amount of tetracycline or

an analog or derivative thereof and in a pharmaceutically acceptable medium compatible with human skin.

54. The pharmaceutical composition of claim 53 further comprising a magnesium salt or organic magnesium compound.

55. The pharmaceutical composition of claim 54 wherein the magnesium salt is magnesium sulfate.

56. A pharmaceutical composition for topical administration for localized chemodenervation comprising a pharmaceutically effective amount of lincosamide or an analog or derivative thereof in a pharmaceutically acceptable medium compatible with human skin.

57. The pharmaceutical composition of claim 56 wherein the lincosamide is clindamycin or lincomycin.

58. The pharmaceutical composition of claim 56 further comprising a magnesium salt or organic magnesium compound.

59. The pharmaceutical composition of claim 58 wherein the magnesium salt is magnesium sulfate.

60. A pharmaceutical composition for topical administration for localized chemodenervation comprising pharmaceutically effective amount of a muscle relaxant or an analog or derivative thereof in a pharmaceutically acceptable medium compatible with human skin.

61. The pharmaceutical composition of claim 60 wherein the muscle relaxant is a non-depolarizing agent.

62. The pharmaceutical composition of claim 61 wherein the non-depolarizing agent is pancuronium, vecuronium, mivacurium or rocuronium.

63. The pharmaceutical composition of claim 60 wherein the muscle relaxant is a depolarizing agent.

64. The pharmaceutical composition of claim 63 wherein the depolarizing agent is succinylcholine or decamethonium.

65. The pharmaceutical composition of claim 60 wherein the muscle relaxant is a magnesium salt or an organic magnesium compound.

66. The pharmaceutical composition of claim 60 further comprising a magnesium salt or organic magnesium compound.

67. The pharmaceutical composition of claim 66 wherein the magnesium salt is magnesium sulfate.

68. A kit comprising the pharmaceutical composition of claim 37, 43, 48, 53, 56, or 60 and instructions on how to administer said pharmaceutical composition for localized chemodenervation.

69. A pharmaceutical composition for topical administration for treating involuntary facial muscle spasms comprising pharmaceutically effective amounts of a composition selected from the group consisting of aminoglycoside antibiotic, polymyxin, tetracycline, lincosamide, muscle relaxant and plant extract, or an analog or derivative thereof and a magnesium salt or organic magnesium compound in a pharmaceutically acceptable medium compatible with human skin.

70. The method of claim 69, wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

71. The pharmaceutical composition of claim 69 wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

72. The pharmaceutical composition of claim 69 wherein the plant extract is toosendanin, coryneine, banana truck extract, curare or black cohosh

73. The pharmaceutical composition of claim 69 wherein the magnesium salt is magnesium sulfate.

74. A kit comprising the composition of claim 69 and instructions on how to administer said composition to treat involuntary facial muscle spasms.

75. A pharmaceutical composition for topical administration for reducing facial wrinkles comprising pharmaceutically effective amounts of a composition selected from the group consisting of aminoglycoside antibiotic, polymyxin, tetracycline, lincosamide, muscle relaxant and plant extract, or an analog or derivative thereof and a magnesium salt or organic magnesium compound in a pharmaceutically acceptable medium compatible with human skin.

76. The method of claim 75, wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

77. The pharmaceutical composition of claim 75 wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

78. The pharmaceutical composition of claim 75 wherein the plant extract is toosendanin, coryneine, banana truck extract, curare or black cohosh

79. The pharmaceutical composition of claim 75 wherein the magnesium salt is magnesium sulfate.

80. A kit comprising the composition of claim 75 and instructions on how to administer said composition to reduce facial wrinkles.

81. A pharmaceutical composition for topical administration for treating or reducing neuropathic pain comprising pharmaceutically effective amounts of a composition selected from the group consisting of aminoglycoside antibiotic, polymyxin, tetracycline, lincosamide, muscle relaxant and plant extract, or an analog or derivative thereof and a magnesium salt or organic magnesium compound in a pharmaceutically acceptable medium compatible with human skin.

82. The method of claim 81, wherein the polymyxin is polymyxin B or polymyxin B nonapeptide.

83. The pharmaceutical composition of claim 81 wherein the aminoglycoside antibiotic is selected from the group consisting of amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, streptomycin and tobramycin.

84. The pharmaceutical composition of claim 81 wherein the plant extract is toosendanin, coryneine, banana truck extract, curare or black cohosh

85. The pharmaceutical composition of claim 81 wherein the magnesium salt is magnesium sulfate.

86. A kit comprising the composition of claim 81 and instructions on how to administer said composition to treat or reduce neuropathic pain.